KR101582974B1

KR101582974B1 - Composition for improving skin condition containing the complex extracts of Hydrolyzed Manihot Esculenta Tuber and Chrysanthemum Parthenium

Info

Publication number: KR101582974B1
Application number: KR1020150111448A
Authority: KR
Inventors: 김다애; 이대우; 최성규; 김윤정
Original assignee: (주)더마랩
Priority date: 2015-08-07
Filing date: 2015-08-07
Publication date: 2016-01-06

Abstract

The present invention relates to a cosmetic composition comprising an extract of cassava tuberculosis enzyme and a extract of Fibberiae. The extracts are effective in increasing the expression of moisturizing factors and inhibiting the expression of inflammatory mediators, and have an excellent skin irritation mitigating effect. Thus, cosmetic preparations containing them as active ingredients show excellent effects on skin improvement.

Description

TECHNICAL FIELD The present invention relates to a cosmetic composition for moisturizing and inflammation relief comprising an extract of cassava tuberous enzyme and a extract of Fibberiae as an active ingredient.

The present invention relates to a cosmetic composition comprising a natural plant extract as an active ingredient and specifically relates to a cosmetic composition for skin improvement comprising an extract of cassava tuberculosis derived from natural origin and an extract of Fibberiae, will be.

The human skin undergoes aging process with deterioration of physiological function over time, and the index of aging appears as skin. The causes of skin aging are internal causes and external causes. The skin is exposed to the external environment, and it is often aged due to the influence of external factors. These include internal damage due to ultraviolet rays, external harmful environmental factors and various stresses. These factors reduce the moisture in the stratum corneum, which makes the skin dry and the surface rough. When water loss occurs, keratin is eliminated and it is easy to be exposed to the outside, causing irritation to the stimulation and skin diseases. Dry skin becomes weaker in immune function, and allergies such as itching and atopic dermatitis tend to occur. Therefore, it is important to prevent moisture loss of the skin.

Oxidative stress leads to activation of proteolytic enzymes, damage of biocomponents such as elastic fibers, collagen and elastin cleavage, and hyaluronic acid cleavage, and inhibits skin inflammation and skin immune function, leading to bacterial infection or increased carcinogenicity. Therefore, skin cells should be protected by inhibiting active oxygen production, inhibiting inflammation caused by active oxygen, and increasing skin moisturizing power.

Feverfew is a commonly known plant, Tanacetum parthenium, as febrile chrysanthemum. It has been recognized since medieval times that it exhibits important medical characteristics when taken orally, usually as an antipyretic. Many antipyretics have isolated extracts of the plants, and these extracts have been used for the oral treatment of migraine, arthritis and bronchial diseases (U.S. Pat. No. 4,758,433 and PCT International Publication No. WO 94/06800). Korean Patent Laid-Open Publication No. 2001-0072221 discloses a topical composition containing a flavin chrysanthemum (Tana septemberpartenum) extract and a method for treating and preventing an inflammatory disease using the composition, which comprises an effective amount of an extract of feverfew A method of treating and preventing topical compositions, inflammatory disorders and conditions associated therewith and a method of improving the inflammatory disease of the skin by applying to the patient a topical composition comprising an effective amount of a feverfew extract &Quot;

The present inventors have searched natural products having moisturizing and anti-inflammatory effects such as moisturizing and anti-inflammatory effects and prepared complexes therefrom and studied their activity. When mixed with the extract of cassava tuberculosis enzyme and the extract of Fibberium, And promoting activity, etc., and thus the present invention has been completed.

It is intended to provide a cosmetic composition for skin moisturizing and inflammation relief containing an extract of cassava tuberculosis enzyme and a extract of Fibberiae.

To achieve the above object, according to the present invention, there is provided a cosmetic composition comprising an extract of cassava tuberculosis enzyme and a extract of Fibberiae in an amount of 0.1 to 10% by weight based on the total weight of the cosmetic composition.

The cassava root stem enzyme extract is prepared by hydrolyzing cassava root stem with a hydrolytic enzyme, more preferably? -Glucosidase.

The Fever protein extract is a hot water extract or a solvent extract with at least one solvent selected from the group consisting of water, lower alcohol having 1 to 4 carbon atoms, ethyl acetate, glycerin, ethylene glycol, propylene glycol and butylene glycol.

The cassava root stem enzyme extract and the Feverpear extract are mixed and contained in a weight ratio of 1 to 15: 1 to 15, more preferably 1: 1.

Wherein the cosmetic composition is a moisturizing cosmetic composition characterized by increasing the moisturizing power of the skin by increasing the expression of a moisturizing factor. The cosmetic composition of the present invention has a skin inflammatory mediator expression inhibitory activity, and is a cosmetic composition for relieving inflammation.

The cosmetic composition containing the extract of cassava tuberculosis enzyme and the extract of Fibberium according to the present invention contains a natural extract and is safe. The synergistic action of the extract of cassava tuberculosis enzyme and the extract of pea pau can provide excellent skin moisturizing effect and skin irritation alleviation effect .

Hereinafter, the present invention will be described in more detail.

The present invention relates to a cosmetic composition comprising an extract of cassava tuberculosis enzyme and a extract of Fibberiae.

Cassava (cassava) is a major habitat and planting site of the Americas tropical region. Cassava is a perennial plant that has prominent fan-shaped leaves, similar to castor leaves but deeply rooted and composed of fleshy roots. It is cultivated to obtain tubers throughout the tropics, making cassava flour, bread, tapioca, and alcoholic beverages. Foods such as the viscous fufu in West Africa and bamimush in Jamaica are also made into cassava. On the other hand, tapioca starch refers to vegetable starch (starch) collected from the roots of cassava. The roots of cassava contain 0 ~ 30% of starch, which is then washed with water to precipitate starch and dried to make tapioca. Starch is a plant-stored carbohydrate and is used as an energy source for humans and animals as a food ingredient. In addition to foodstuffs, starch has been widely used in various industries such as pharmaceutical paper and cosmetics, and now has potential for biodegradable new materials in various fields.

Feverfew is Tanacetum parthenium, a commonly known plant as a feverfew. It has been recognized since medieval times that it exhibits important medical characteristics when taken orally, usually as an antipyretic. Many antipyretics have a separate extract of the plant, and these extracts have been used to treat migraine, arthritis and bronchial diseases orally.

As an effective ingredient of flower chrysanthemums, apigenin-7-glucoside, apigenin-7-glucuronide, 1-beta-hydroxy arbusurin, 6-hydroxycamprole- 7-4'-trimethyl ether (tannethine), 6-hydroxycamproprole-3,7-dimethyl ether, 8-β-lyoxin, 10-epicanin, ascorbic dimethyl ether, 8- 10-epicanin, ascorbic acid, beta-carotene, calcium, chromium, chrysanthemolide, chrysanthemamine and the like.

According to one embodiment of the present invention, the cassava extract and the Fibberi extract are a hot-water extract or a mixture of water, a lower alcohol having 1 to 4 carbon atoms, ethyl acetate, glycerin, ethylene glycol, propylene glycol and butylene glycol Solvent extract of at least one selected solvent.

The cassava tuberculosis enzyme extract of the present invention is prepared by hydrolysis of the cassava tuberculosis extract with a hydrolytic enzyme, preferably β-glucosidase.

The cassava root stem enzyme extract and the Feverpear extract as an active ingredient are mixed at a weight ratio of 1 to 15: 1 to 15, more preferably 1: 1, to 0.1 to 10 weight% of the total weight of the cosmetic composition do.

The extracts of the cassava tuberculosis enzyme and the fiver pue complex of the present invention were superior in the effect of increasing the expression of moisturizing factors (Test Example 1) and suppressing the expression of inflammation-related factors (Test Example 2) .

The cosmetic composition of the present invention can be manufactured into any of the commonly used formulations and examples thereof include lotion, cream, essence, cleansing foam, cleansing water, pack, body lotion, body oil, body gel, shampoo, Conditioner, hair gel, foundation, lipstick, mascara, make-up base and the like.

[Example]

Hereinafter, the present invention will be described in detail by way of the following examples and test examples, but the present invention is not limited to these examples.

Production Example 1: Preparation of cassava tuberculosis extract

The cassava tubules were washed with purified water and then dried. The resulting solution was heated to 80 ° C to 100 ° C in an extractor (Cosmos-660, manufactured by Kyoreya Seisakusho Co., Ltd.) 3 times.

The precipitate was filtered through 300 mesh filter paper, and the precipitate was filtered twice using filter paper of Edbentek No. 5 and Wattman GFC 150 mm filter paper. The mixture was concentrated using a vacuum condenser (Coolace CCA-1100, EYELA) at a temperature of 40 ° C to 50 ° C and then filtered through a spray dryer (B-290, BUCHI) , And dried under the conditions of 100% efficiency (35 cm3 / hr), pump efficiency 25% (7.5 ml / min), Nozzle Cleaner 4 and 30 mm (357 liters / hour) 10 g of the title powder was obtained.

Production Example 2: Preparation of cassava tuberous enzyme extract

10 g of the extracted powder of cassava tuber extract prepared in Preparation Example 1 was added to 500 ml of acetate buffer (pH 4.0) and 25 ml of? -Glucosidase, and the mixture was reacted at 55 ° C for 4 hours at 100 rpm. Next, the mixture was heated at 90 DEG C for 5 minutes to complete the enzyme reaction, and the reaction mixture was concentrated in vacuo. The concentrate was dried at 60 DEG C for 30 hours. The precipitate was filtered through 300 mesh filter paper, and the precipitate was filtered twice using filter paper of Edbentek No. 5 and Wattman GFC 150 mm filter paper. The mixture was concentrated using a vacuum condenser (Coolace CCA-1100, EYELA) at a temperature of 40 ° C to 50 ° C and then filtered through a spray dryer (B-290, BUCHI) (357 liters / hour), 100% efficiency (35 cm3 / hr), pump efficiency 25% (7.5 ml / min), Nozzle Cleaner 4 and flow meter Rotameter) 10 g of the title extract powder was obtained.

Production Example 3: Preparation of Fibberium extract

100 g of feverfew dried in purified water was added to a 5-fold weight 70% ethanol solution as an extraction solvent, heated to 80 ° C to 100 ° C with an extractor (Cosmos-660, And extracted three times in total.

Example 1: Preparation of a mixture of extract of cassava tuberculosis enzyme and Feverfew extract

The mixture of cassava tuberose enzyme extract and Fever protein extract prepared in Preparation Examples 2 and 3 was mixed at a ratio of 1: 1, respectively, as shown in Table 1 below.

The 1: 1 mixture of the cassava extract of Preparation Example 1, the extract of Fibberiae of Preparation Example 3, the extract of cassava rootstock and the extract of Fibberiae were respectively as Comparative Examples 1 to 3.

Natural product Example 1 Comparative Example 1 Comparative Example 2 Comparative Example 3 Cassava tuber extract
(Production Example 1) - 60g - - Fever Pew Extract
(Production Example 3) - - 60g - Mixture of cassava tuberculosis extract and Fibberium extract - - - 60g Mixture of cassava tuberous enzyme extract and Fibberium extract 60g - - -

Test Example 1: Confirmation of cytotoxicity

To confirm cytotoxicity, fibroblasts were inoculated into IMDM medium supplemented with 10% FBS at a cell concentration of 5 × 10 ⁵ cells and cultured in a 37 ° C. 5% CO ₂ incubator for 24 hours. After the culture, the culture medium was removed, and the extract prepared in the above Preparation Examples and Examples was diluted with dimethyl sulfoxide to give sample concentrations of 50, 100, 500 and 1000 μg / ml. The diluted solution was treated and cultured for 24 hours 100 ml of MTT (3- [4,5-dimethylthiazol-2yl] -2,5-diphenyltetrazoliumboromide, Sigma, USA) solution was added to each well (3 mg / ml) for further 4 hours. After removing the supernatant, 150 μl of dimethylsulfoxide was added, and the resulting formazan was shaken by shaking for 30 minutes. Absorption was measured at 540 nm using a multimicroplate reader (Molecular device Spectra max 190). Cell viability was calculated according to the following equation and the results are shown in Table 2 below.

Cell survival rate (%) = absorbance of sample-added group / absorbance of control group 100

Sample concentration
(占 퐂 / ml) Cell survival rate (%) Comparative Example 1 Comparative Example 2 Comparative Example 3 Example 1 0 100 100 100 100 50 100 100 100 100 100 100 100 100 100 500 100 100 100 100 1000 96.6 97.7 96.4 98.9

As shown in the results of Table 2 above, all of the samples to which the mixture of cassava tuberculosis extract, Feverfew extract, cassava tuberculosis extract and Feverfew extract and the mixture of cassava tuber enzyme extract and Feverfew extract were applied had a concentration of 500 μg / ml And the cell viability was confirmed to have no effect on cytotoxicity. Therefore, it was confirmed that there is no problem in safety.

Test Example 2: Confirmation of inhibitory effect of inflammatory mediator

RAW264.7 cells were cultured in DMEM medium supplemented with 10% FBS at 5 × 10 ⁵ cells / well, inoculated on a 12-well plate and incubated for 18 hours. After incubation, starvation was maintained for 12 hours. LPS was treated with 10 ng / mL of LPS and incubated for 24 hours. RNA was extracted from the cultured cells and the inhibition rate of TNF-α expression was confirmed by reverse transcription polymerase chain reaction (RT-PCR). The inhibition rate of TNF-a expression was calculated by the following formula, and the results are shown in Table 3 below. Dexamethasone was used as a control.

TNF-α expression level (%) = (sample TNF-α expression level / control group TNF-α expression level) × 100

Name of sample Treatment concentration (w / v%) TNF-α inhibition rate (%) Example 1 0.1 79.21 Comparative Example 1 0.1 71.3 Comparative Example 2 0.1 72.5 Comparative Example 3 0.1 72.2 Dexamethason 0.1 73.2

As shown in Table 3, TNF-α inhibitory effect was confirmed in all of the samples tested at the concentration of 0.1 (wt / v)%. In particular, Example 1, which contained the extract of cassava tuberculosis enzyme and the extract of Fibberiae, showed an excellent TNF-α inhibitory effect as compared with Comparative Examples 1 to 3.

Test Example 3: Confirmation of increasing effect of moisturizing factor

CCD-986Sk cells were adjusted to 5 × 10 ⁵ cells / well using IMDM medium supplemented with 10% FBS, and then inoculated on a 12-well plate and cultured for 18 hours. After culturing, the samples were treated and incubated for 24 hours. RNA was extracted from the cultured cells and the expression of Hyaluronan Synthase-3 (HAS-3) was confirmed by reverse transcription polymerase chain reaction (RT-PCR). The expression level of HAS-3 was calculated by the following equation, and the results are shown in Table 4 below. As a control group, hyaluronic acid was used.

(%) = (Expression amount of sample HAS-3 / expression amount of control HAS-3) × 100

Name of sample Treatment concentration (w / v%) HAS-3 growth rate (%) Example 1 0.1 91.0 Comparative Example 1 0.1 84.5 Comparative Example 2 0.1 83.9 Comparative Example 3 0.1 85.1 Hyaluronic Acid 0.1 83.7

As shown in Table 4, the best growth rate of HAS-3 was shown in Example 1 containing the cassava tuber enzyme extract and the Fever protein extract.

Test Example 4: Confirmation of hyaluronidase activity inhibitory effect

The inhibitory effect of hyaluronidase activity was measured and applied by Morgan-Elson method. The final enzyme activity of hyaluronidase was 400 NF unit / ml, the final concentration of HA was 0.4 mg / ml, and inactivated hyaluronidase was used using Compound 48/80 buffer (0.1 mg / ml) The hyaluronidase activity was measured mainly on the inhibitory action of the activation step of the enzyme. The sample was dissolved in a buffer to prepare a sample solution. As a control, a buffer solution was used instead of the sample solution. As a control group, hyaluronic acid was used. The inhibitory activity (%) of the hyaruronidase was calculated by the following equation.

Hyaluronidase activity inhibition rate (%) = [(A-B) / A] 100

A: Enzyme activity of well without addition of sample

B: Enzyme activity of the well to which the sample was added

density(%) Inhibitory effect of hyaluronidase activity (%) Example 1 Comparative Example 1 Comparative Example 2 Comparative Example 3 Hyaluronic Acid 0.5 7.2 6.7 5.7 8.5 8.0 1.0 20.6 13.5 17.5 21.3 20.3 3.0 49.8 35.8 37.8 47.5 45.6 5.0 89.3 58.9 56.7 86.7 88.7

As shown in Table 5, the best inhibitory effect was shown in Example 1, which contained the extract of cassava tuberculosis enzyme and the extract of Fibberiae, as compared with the other comparative examples.

Example 2: Preparation of serum containing cassava tuberous enzyme extract and Feverfew extract

A serum containing a cassava root enzyme extract and a fiver extract (Example 1) was prepared according to a conventional method with the composition and content shown in Table 6 below.

Raw material Content (% by weight) Cassava tuberous enzyme extract and Fibberium extract
(Example 1) 1.0 Wax 1.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Mineral oil 10.0 Sorbitan stearate 0.5 Pro-type glycerin monostearate 1.0 Stearic acid 1.5 Glyceryl stearate /
FAGE-400 stearate 1.0 Propylene glycol 3.0 Carboxy polymer 0.1 Triethanolamine 0.1 Phenoxyethanol Suitable amount Purified water To 100

Example 3: Preparation of a cream containing an extract of cassava tuberculosis enzyme and Feverfew extract

The cream containing the cassava root enzyme extract and the Fibber Pee extract (Example 1) was prepared according to a conventional method with the composition and contents shown in Table 7 below.

Raw material Content (% by weight) Cassava tuberous enzyme extract and Fibberium extract
(Example 1) 1.0 Shea Butter 2.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.8 Mineral oil 10.0 Dimethicone 3.0 Sorbitan stearate 0.5 Pro-type glycerin monostearate 1.0 Cetearyl alcohol 2.0 Glyceryl stearate /
FAGE-400 stearate 1.0 Propylene glycol 3.0 Carboxy polymer 0.25 Triethanolamine 0.25 Phenoxyethanol Suitable amount Purified water To 100

Test Example 5: Confirmation of formulation stability

The formulations prepared in Examples 2 and 3 were stored in an opaque glass container in a room, a refrigerator and an incubator kept constant at room temperature (25 ° C), cold (4 ° C) and constant temperature (50 ° C) Observed (discolored, detached and separated), and the stability was confirmed. The results are shown in Table 8.

Temperature condition Stability verification (discoloration, removal and separation) Example 2 Example 3 Room temperature (25 캜) 0 0 Refrigerated (4 ℃) 0 0 Constant temperature (50 ° C) 0 0

0: No change 1: Minute change 2: Change 3: Extreme change

As shown in the above table, it was confirmed that the coloring and separation phenomenon did not appear and was stable under the temperature conditions of 25 ° C, 4 ° C and 0 ° C in both of the formulations of Examples 2 and 3.

Claims

A mixture of a cassava root stem enzyme extract prepared by hydrolyzing a cassava root stem with? -Glucosidase and a Fibberium extract at a weight ratio of 1: 1 is contained in an amount of 0.1 to 10% by weight based on the total weight of the cosmetic composition A cosmetic composition for moisturizing and relieving inflammation.

delete

The cosmetic composition for skin moisturizing and inflammation relief according to claim 1, wherein the cosmetic composition increases the moisturizing power of the skin through an increase in the expression of a moisturizing factor.

The cosmetic composition for skin moisturizing and inflammation relief according to claim 1, wherein the cosmetic composition has a skin inflammatory mediator expression inhibitory activity.